Outcomes of CDK4/6 Inhibitors vs Weekly Paclitaxel in the Treatment of Patients With ER+/HER2− Advanced Breast Cancer With Impending or Established Visceral Crisis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
Breast Cancer Res Treat 2023 Aug 16;[EPub Ahead of Print], R Behrouzi, AC Armstrong, SJ HowellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.